[go: up one dir, main page]

HUP9900767A2 - Pirrolidinil-hidroxámsav-származékok és intermedierjeik, előállításuk és a vegyületeket tartalmazó gyógyászati készítmények - Google Patents

Pirrolidinil-hidroxámsav-származékok és intermedierjeik, előállításuk és a vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP9900767A2
HUP9900767A2 HU9900767A HUP9900767A HUP9900767A2 HU P9900767 A2 HUP9900767 A2 HU P9900767A2 HU 9900767 A HU9900767 A HU 9900767A HU P9900767 A HUP9900767 A HU P9900767A HU P9900767 A2 HUP9900767 A2 HU P9900767A2
Authority
HU
Hungary
Prior art keywords
alkyl
hydroxyl
intermediates
compounds
general formula
Prior art date
Application number
HU9900767A
Other languages
English (en)
Inventor
Fumitaka Ito
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of HUP9900767A2 publication Critical patent/HUP9900767A2/hu
Publication of HUP9900767A3 publication Critical patent/HUP9900767A3/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)

Abstract

A cím szerinti céltermék (I) általánős és intermedierjei (II)általánős képleteiben A jelentése hidrőgénatőm, hidrőxil- vagy OYáltalánős képletű csőpőrt, ahől Y jelentése hidrőxil védőcsőpőrt, Arjelentése adőtt esetben egy vagy több halőgénatőmmal, hidrőxil-,alkil-, alkőxi-, triflűőr-metil-, alkőxi-alkőxi- és/vagy karbőxi-alkőxi-csőpőrttal szűbsztitűált fenilcsőpőrt; X jelentése fenil-,naftil-, bifenil-, indanil-, benzőfűranil-, benzőtienil-, 1-tetralőn-6-il-, alkilén-diőxi-, piridil-, fűril- vagy tienilcsőpőrt, amelyekadőtt esetben legfeljebb 3 halőgénatőmmal, alkil-, alkőxi-, hidrőxil-,nitrő-, triflűőr-metil- és/vagy metil-szűlfőnil-csőpőrttal lehetnekhelyettesítve; R jelentése hidrőgénatőm, alkil- vagy hidrőxilvédőcsőpőrt. A vegyületek és gyógyszerkészítmények, melyek avegyületeket tartalmazzák, hasznős fájdalőmcsillapító, gyűlladásgátló,vízhajtó, érzéstelenítő vagy neűrőprőtektív szerek, vagy a bélműködésibetegségek, példáűl alhasi fájdalőm vagy szélütés kezelésére szőlgálószerek emlősöknél, különösen az embernél. A találmány az (I) általánősképletű hidrőxámsavszármazékők előállítása mellett kiterjed a (II)általánős képletű intermedierek előállítására is. ŕ
HU9900767A 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid derivatives and their intermediates, preparation thereof, pharmaceutical compositions containing these compounds HUP9900767A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9500631 1995-03-31

Publications (2)

Publication Number Publication Date
HUP9900767A2 true HUP9900767A2 (hu) 1999-07-28
HUP9900767A3 HUP9900767A3 (en) 2001-01-29

Family

ID=14125824

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9900767A HUP9900767A3 (en) 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid derivatives and their intermediates, preparation thereof, pharmaceutical compositions containing these compounds

Country Status (35)

Country Link
US (2) US5952369A (hu)
EP (1) EP0817772B1 (hu)
JP (1) JP3035356B2 (hu)
KR (1) KR100258657B1 (hu)
AP (1) AP625A (hu)
AR (1) AR002729A1 (hu)
AT (1) ATE231840T1 (hu)
AU (1) AU693336B2 (hu)
BG (1) BG62611B1 (hu)
BR (1) BR9607750A (hu)
CA (1) CA2213815C (hu)
CZ (1) CZ306497A3 (hu)
DE (1) DE69626009T2 (hu)
DK (1) DK0817772T3 (hu)
ES (1) ES2188743T3 (hu)
HR (1) HRP960141A2 (hu)
HU (1) HUP9900767A3 (hu)
IL (2) IL117440A0 (hu)
IS (1) IS4547A (hu)
LV (1) LV11971B (hu)
MA (1) MA23832A1 (hu)
NO (1) NO974513L (hu)
NZ (1) NZ304113A (hu)
OA (1) OA10518A (hu)
PE (1) PE43397A1 (hu)
PL (1) PL322652A1 (hu)
RU (1) RU2144917C1 (hu)
SI (1) SI9620039A (hu)
SK (1) SK129897A3 (hu)
TN (1) TNSN96045A1 (hu)
TR (1) TR199701082T1 (hu)
TW (1) TW408111B (hu)
WO (1) WO1996030339A1 (hu)
YU (1) YU18696A (hu)
ZA (1) ZA962476B (hu)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9701042A (es) * 1996-02-07 1998-05-31 Pfizer Compuestos del acido hidroxamico.
TNSN97092A1 (ar) 1996-09-18 1999-12-31 Agouron Pharma مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
KR100483221B1 (ko) * 1996-12-02 2005-04-15 교린 세이야꾸 가부시키 가이샤 N-치환된 피롤리딘 유도체 및 이의 제조방법
EP0973737A4 (en) * 1997-01-10 2000-04-26 Merck & Co Inc EFFECTIVE SYNTHESIS OF A CHIRAL MEDIATOR
EP0982297A3 (en) * 1998-08-24 2001-08-01 Pfizer Products Inc. Process for the preparation of hydroxy-pyrrolidinyl hydroxamic acid derivatives being opioid kappa receptor agonists
KR100295740B1 (ko) * 1998-09-17 2001-11-05 박영구 N-치환된-하이드록시고리화알킬아민유도체의제조방법
US6444829B1 (en) * 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
MXPA03009927A (es) 2001-04-30 2004-01-29 Pfizer Prod Inc Procedimiento para preparar compuestos de hidroxipirrolidinietilamina utiles como agonistas de kappa.
US7091357B2 (en) * 2001-12-26 2006-08-15 University Of Kentucky Research Foundation Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
AU2003269399A1 (en) * 2002-11-01 2004-05-25 Pfizer Products Inc. Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
GB0821010D0 (en) * 2008-11-17 2008-12-24 Univ Warwick Plant development control composition
US9493451B2 (en) 2011-05-16 2016-11-15 Bionomics Limited Amine derivatives as potassium channel blockers
DK2822928T3 (en) 2012-03-05 2019-03-11 Dr Reddys Laboratories Ltd SUBSTITUTED HETEROCYCLIC ACETAMIDS AS CAPE-OPIOID RECEPTOR (CHOR) AGONISTS
GB201210395D0 (en) * 2012-06-11 2012-07-25 Syngenta Participations Ag Crop enhancement compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3268539A (en) * 1963-05-20 1966-08-23 Universal Oil Prod Co Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

Also Published As

Publication number Publication date
WO1996030339A1 (en) 1996-10-03
DE69626009D1 (de) 2003-03-06
TW408111B (en) 2000-10-11
MA23832A1 (fr) 1996-10-01
HRP960141A2 (en) 1997-10-31
BG62611B1 (bg) 2000-03-31
KR19980703476A (ko) 1998-11-05
NO974513D0 (no) 1997-09-29
LV11971B (en) 1998-06-20
SK129897A3 (en) 1998-11-04
CZ306497A3 (cs) 1998-07-15
TR199701082T1 (xx) 1998-02-21
NZ304113A (en) 1999-01-28
JPH11501048A (ja) 1999-01-26
PL322652A1 (en) 1998-02-16
BR9607750A (pt) 1998-06-30
EP0817772A1 (en) 1998-01-14
ZA962476B (en) 1997-09-29
PE43397A1 (es) 1997-10-13
DK0817772T3 (da) 2003-05-19
IL129479A0 (en) 2000-02-29
RU2144917C1 (ru) 2000-01-27
HUP9900767A3 (en) 2001-01-29
SI9620039A (sl) 1998-08-31
AR002729A1 (es) 1998-04-29
LV11971A (lv) 1998-02-20
BG101896A (en) 1999-01-29
AP9600791A0 (en) 1996-04-30
AU693336B2 (en) 1998-06-25
AU5121196A (en) 1996-10-16
KR100258657B1 (ko) 2000-07-01
CA2213815C (en) 2001-12-18
IS4547A (is) 1997-08-19
IL117440A0 (en) 1996-07-23
TNSN96045A1 (fr) 2005-03-15
EP0817772B1 (en) 2003-01-29
AP625A (en) 1997-12-24
JP3035356B2 (ja) 2000-04-24
YU18696A (sh) 1999-06-15
ES2188743T3 (es) 2003-07-01
OA10518A (en) 2002-04-22
ATE231840T1 (de) 2003-02-15
US5952369A (en) 1999-09-14
NO974513L (no) 1997-09-29
MX9707454A (es) 1998-07-31
US6110947A (en) 2000-08-29
CA2213815A1 (en) 1996-10-03
DE69626009T2 (de) 2003-08-14

Similar Documents

Publication Publication Date Title
HUP9904221A2 (hu) Ciklooxigenáz-2 inhibitorok alkalmazása neoplázia kezelésére és megelőzésére alkalmas gyógyszerkészítmények előállítására
HUP9900767A2 (hu) Pirrolidinil-hidroxámsav-származékok és intermedierjeik, előállításuk és a vegyületeket tartalmazó gyógyászati készítmények
EP0371731A3 (en) Quinazolinone derivatives
HUP9902121A2 (hu) Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
HUP9600448A2 (hu) Naftilvegyületek, e vegyületeket tartalmazó gyógyszerkészítmények, eljárás előállításukra, intermedierjeik és alkalmazásuk
GB9930610D0 (en) Tricyclic vascular damaging agents
NO855355L (no) Fremgangsmaate for fremstilling av naftalenderivater.
ATE13286T1 (de) Pharmazeutisch aktive phenylcarbonsaeurederivate.
FR2391209A1 (fr) Aminoalkyl thiophenes, utiles comme medicaments, leur preparation et compositions en contenant
FR2421889A1 (fr) Nouveaux derives d'acide thiazolidinecarboxylique-4 utiles comme medicaments antihypertenseurs et procedes pour leur preparation
FR2361901A1 (fr) Derives de substitution de nucleotides et medicament contenant ces substances
RU94044454A (ru) Ингибитор аутоимунных заболеваний
PT912185E (pt) Novas formulacoes farmaceuticas contendo derivados de ester nitrato de esteroides proveitosos como farmacos anti-inflamatorios
HUP0003571A2 (hu) 6,9-Hídkötésű eritromicin-származékok
HUP9802121A2 (hu) Imidazolinszármazékok, eljárás előállításukra és e vegyületeket tartalmazó gyógyszerkészítmények
NO158017C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazolderivater.
HUP9900186A2 (hu) Lamellarin alkaloidok gyógyászati alkalmazása és az ezeket tartalmazó gyógyszerkészítmények
HUP0104520A2 (hu) Szubsztituált benzo[de]izokinolin-1,3-dion-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyászati készítmények
HUP9701660A2 (hu) 10,13,15-trioxa-triciklo[9.2.1.1. 9.6]pentadekanon-származékok, eljárás ezek előállítására, és az e vegyületeket tartalmazó gyógyászati készítmények
KR910002437A (ko) 항염증성 조성물, 항알레르기성 조성물 또는 이들 혼합성질의 조성물
ATE72447T1 (de) Chartreusinderivate und salze, diese enthaltende antitumorzusammensetzungen und verfahren zu ihrer herstellung.
FR2744445B1 (fr) Composes biphenyles nouveaux et/ou a titre de medicament, compositions pharmaceutiques les contenant, leur procede de preparation et les intermediaires de ce procede
HUP9701016A2 (hu) Teofillinszármazékok alkalmazása sokkos állapotok kezelésére használható gyógyszerkészítmények előállítására, új xantinvegyületek, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
HUP9904696A2 (hu) COX-2 Enzim indén-típusú inhibitorai
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására